Strike Pharma AB

Great news 🎉 we just received the notification that we have been granted our first patent approval ✅of our innovative precision immunotherapy technology. Fun fact, it has been granted in the expected soon to be second largest🥈pharmaceutical market 📈 ➡️➡️➡️Japan 🇯🇵👊. Read more ➡️ https://lnkd.in/dmB79UY7 Marten Winge Pierre Dönnes Tina Furebring Sara Mangsbo Niclas Stiernholm Eir Ventures Flerie Uppsala universitet Invest AB SciLifeLab Drug Discovery & Development SciLifeLab Helena Persson Lotsholm AWA SLU Holding AB Almi Invest

We are thrilled that our CSO Prof Mangsbo is one of the speakers at this year's PEGS Europe in Barcelona, November 5-7. Be sure to attend her presentation and reach out if you have any queries or need further discussion on the topic! #PEGSEurope #ADAC #ADC #conjugate #therapy #targetedtherapy Sara Mangsbo Uppsala universitet Invest AB Eir Ventures Flerie Olle Wahlqvist Tina Furebring Marten Winge Pierre Dönnes Mimi Langley Cambridge Healthtech Institute

We are so happy to share that we have received funding from BIO-X Accelerate💥. With the support from the call that focus 🎯in on IMPACT we will pursue our work on the Adaptable Drug Affinity Conjugate (ADAC) technology💊, to provide a technology for targeted delivery of oligonucleotide-based therapies! Together with our collaborators Jonas Nilsson Tommy Lidström Ulf Tedebark OLIGOMED - Oligonucleotides for Medical Applications and our investors we can ramp up our efforts 👊🎉 STUNS Life science European Regional Development Fund Tillvaxtverket Eir Ventures Flerie Uppsala universitet Invest AB Olle Wahlqvist Almi Invest SLU Holding AB https://lnkd.in/dgxZ2wKv About BIO-X BIO-X Accelerate is a program with the goal of accelerating the development of innovation in the health and/or life science industry. The program uses an industrial approach to support life science-related projects that could fulfill well-defined needs and create IMPACT in healthcare, industry and society. Selected companies receive funding for their projects as well as continued support and access to experts within the BIO-X network. BIO-X Accelerate with the theme IMPACT is a project by STUNS with strategic partners UIC, Connect Uppsala, Create Business Incubator, Lead (Business Incubator), Inkubera and supporting partners Linköping University Innovation, Uppsala University and Örebro University Holding. The project is financed by European Regional Development Fund (ERDF) through The Swedish Agency for Economic and Regional Growth via STUNS. About STUNS STUNS is the foundation for collaboration between the universities in Uppsala, business and society. STUNS Life science is a strategic hub for collaboration between private and public actors to contribute to sustainable knowledge-based growth - in life science, health and neighboring disciplines.

Our co-founder 👊took the stage (bold move 😁) at the European Investment Fund (EIF) #30yearsbold celebration to discuss future #metatrends 💥 What she said? ✅Europe must and can lead the transition that makes use of the digital era to treat the right patient with the right drug. ✅Immunotherapy must become more precise and we must fuse the use of different drug classes ✅Targeted therapies cannot just contain classical toxic cargoes, time to look beyond tradition and prepare ourselves for a disruption era of new drug classes 🥳 ✅These novel therapies must also form a basis for sustainable healthcare development ahead for improved equality in care ❤️ but still with maintained focus on patient centered care

Listen to a new podcast 🤗with a focus on healthcare and innovation with our founder and CSO Sara Mangsbo ⬇️⬇️⬇️ #innovation #healthcare #futuremedicine #digitaltransformation #uppsala

The Adaptable Drug Affinity Conjugate (ADAC) technology is presented in this review presenting the future outlook for novel disruptive CD40 agonistic antibodies on the horizon 💉⬇️🤗 https://lnkd.in/drWJ6xbr #drugdevelopment #CD40 #agonistic #antibodydrugconjugates

Well done Elvira Björklund 💪🚀 we are happy that you investigate antibodies and peptides in depth with support from new in vitro tools developed by fantastic researchers at The Swedish Drug Delivery Center (SweDeliver) #science #adac #adc #therapeutics

👇🏽👇🏽👇🏽 great to see that the Adaptable Drug Affinity Conjugate technology, when combined with CD40 agonistic therapy, is getting attention by the scientific community 💫. Hope to share new publications on the development work of STRIKE2001 during 2024 🥳🚀 #topdownloadedarticle

If you are attending BIO-Europe Spring next week, why not take the opportunity to hear about the latest developments at Strike Pharma? Pierre Dönnes, our Vice President Neoantigen Discovery, https://lnkd.in/dChHVx7B will be happy to meet you. #biotechnology #cancerimmunotherapy #immunooncology #therapeuticvaccines

Our CSO will be in Copenhagen next week 🇩🇰, join her 👇🏽🤗